A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells.

S. S. Bacus, E. Huberman, D. Chin, K. Kiguchi, S. Simpson, Marc E Lippman, R. Lupu

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

The human erbB-2 oncogene encodes a tyrosine kinase receptor. A ligand for the erbB-2 receptor (gp30), with an apparent molecular weight of 30,000, was reported to modulate the growth of cells overexpressing erbB-2. Whereas low concentrations of gp30 induced proliferation of these cells, higher concentrations inhibited their growth. To elucidate the cellular mechanisms underlying cell growth inhibition by gp30, we tested the effect of this ligand on cell growth and differentiation of the human breast cancer cells AU-565 and MDA-MB-453 (which overexpress erbB-2) and MCF-7 cells (which express low levels of this protooncogene). Ligand concentrations that inhibited growth in cells overexpressing erbB-2 induced apparent differentiation of cells with a more mature phenotype, i.e., with characteristics such as inhibited cell growth, altered cytoplasmic and nuclear morphology, and increased synthesis of milk components (casein and lipids). No significant effect of the ligand was observed in the human breast cancer cell line MCF-7. Concomitant with the induction of differentiation in AU-565 and MDA-MB-453 cells, the erbB-2 protein was translocated from membrane to the cytoplasm and perinuclear sites. These findings indicate that ligand-induced growth inhibition in cells overexpressing erbB-2 is associated with an apparent induction of differentiation.

Original languageEnglish
Pages (from-to)401-411
Number of pages11
JournalCell growth & differentiation : the molecular biology journal of the American Association for Cancer Research
Volume3
Issue number7
StatePublished - Jul 1 1992
Externally publishedYes

Fingerprint

Oncogene Proteins
Breast Neoplasms
Ligands
Growth
Cell Differentiation
ErbB-2 Receptor
MCF-7 Cells
Receptor Protein-Tyrosine Kinases
Caseins
Oncogenes
Cytoplasm
Milk
Molecular Weight
Cell Proliferation
Phenotype
Lipids
Cell Line
Membranes
Proteins

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. / Bacus, S. S.; Huberman, E.; Chin, D.; Kiguchi, K.; Simpson, S.; Lippman, Marc E; Lupu, R.

In: Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, Vol. 3, No. 7, 01.07.1992, p. 401-411.

Research output: Contribution to journalArticle

@article{fb65b4568a9f4d0e908ace082f25854a,
title = "A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells.",
abstract = "The human erbB-2 oncogene encodes a tyrosine kinase receptor. A ligand for the erbB-2 receptor (gp30), with an apparent molecular weight of 30,000, was reported to modulate the growth of cells overexpressing erbB-2. Whereas low concentrations of gp30 induced proliferation of these cells, higher concentrations inhibited their growth. To elucidate the cellular mechanisms underlying cell growth inhibition by gp30, we tested the effect of this ligand on cell growth and differentiation of the human breast cancer cells AU-565 and MDA-MB-453 (which overexpress erbB-2) and MCF-7 cells (which express low levels of this protooncogene). Ligand concentrations that inhibited growth in cells overexpressing erbB-2 induced apparent differentiation of cells with a more mature phenotype, i.e., with characteristics such as inhibited cell growth, altered cytoplasmic and nuclear morphology, and increased synthesis of milk components (casein and lipids). No significant effect of the ligand was observed in the human breast cancer cell line MCF-7. Concomitant with the induction of differentiation in AU-565 and MDA-MB-453 cells, the erbB-2 protein was translocated from membrane to the cytoplasm and perinuclear sites. These findings indicate that ligand-induced growth inhibition in cells overexpressing erbB-2 is associated with an apparent induction of differentiation.",
author = "Bacus, {S. S.} and E. Huberman and D. Chin and K. Kiguchi and S. Simpson and Lippman, {Marc E} and R. Lupu",
year = "1992",
month = "7",
day = "1",
language = "English",
volume = "3",
pages = "401--411",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells.

AU - Bacus, S. S.

AU - Huberman, E.

AU - Chin, D.

AU - Kiguchi, K.

AU - Simpson, S.

AU - Lippman, Marc E

AU - Lupu, R.

PY - 1992/7/1

Y1 - 1992/7/1

N2 - The human erbB-2 oncogene encodes a tyrosine kinase receptor. A ligand for the erbB-2 receptor (gp30), with an apparent molecular weight of 30,000, was reported to modulate the growth of cells overexpressing erbB-2. Whereas low concentrations of gp30 induced proliferation of these cells, higher concentrations inhibited their growth. To elucidate the cellular mechanisms underlying cell growth inhibition by gp30, we tested the effect of this ligand on cell growth and differentiation of the human breast cancer cells AU-565 and MDA-MB-453 (which overexpress erbB-2) and MCF-7 cells (which express low levels of this protooncogene). Ligand concentrations that inhibited growth in cells overexpressing erbB-2 induced apparent differentiation of cells with a more mature phenotype, i.e., with characteristics such as inhibited cell growth, altered cytoplasmic and nuclear morphology, and increased synthesis of milk components (casein and lipids). No significant effect of the ligand was observed in the human breast cancer cell line MCF-7. Concomitant with the induction of differentiation in AU-565 and MDA-MB-453 cells, the erbB-2 protein was translocated from membrane to the cytoplasm and perinuclear sites. These findings indicate that ligand-induced growth inhibition in cells overexpressing erbB-2 is associated with an apparent induction of differentiation.

AB - The human erbB-2 oncogene encodes a tyrosine kinase receptor. A ligand for the erbB-2 receptor (gp30), with an apparent molecular weight of 30,000, was reported to modulate the growth of cells overexpressing erbB-2. Whereas low concentrations of gp30 induced proliferation of these cells, higher concentrations inhibited their growth. To elucidate the cellular mechanisms underlying cell growth inhibition by gp30, we tested the effect of this ligand on cell growth and differentiation of the human breast cancer cells AU-565 and MDA-MB-453 (which overexpress erbB-2) and MCF-7 cells (which express low levels of this protooncogene). Ligand concentrations that inhibited growth in cells overexpressing erbB-2 induced apparent differentiation of cells with a more mature phenotype, i.e., with characteristics such as inhibited cell growth, altered cytoplasmic and nuclear morphology, and increased synthesis of milk components (casein and lipids). No significant effect of the ligand was observed in the human breast cancer cell line MCF-7. Concomitant with the induction of differentiation in AU-565 and MDA-MB-453 cells, the erbB-2 protein was translocated from membrane to the cytoplasm and perinuclear sites. These findings indicate that ligand-induced growth inhibition in cells overexpressing erbB-2 is associated with an apparent induction of differentiation.

UR - http://www.scopus.com/inward/record.url?scp=0026899636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026899636&partnerID=8YFLogxK

M3 - Article

C2 - 1358180

AN - SCOPUS:0026899636

VL - 3

SP - 401

EP - 411

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 7

ER -